Comparative efficacy and safety of biosimilar Bmab 1200 versus reference ustekinumab in moderate-to-severe plaque psoriasis: 52-week findings from the Phase 3 STELLAR-2 trial.
- DOI
- 10.1080/14712598.2025.2576506
- Published
- 2025 Oct
- Container
- Expert opinion on biological therapy
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1080/14712598.2025.2576506,
title = {Comparative efficacy and safety of biosimilar Bmab 1200 versus reference ustekinumab in moderate-to-severe plaque psoriasis: 52-week findings from the Phase 3 STELLAR-2 trial.},
author = {Szepietowski JC and Reich A and Feldman SR and Pulka G and Mekokishvili L and Tsiskarishvili N and Svarca I and Poder A and Singh G and Deodhar S and Kumar K and Marwah A and Loganathan S and Wolff-Holz E and Athalye SN},
year = {2025},
journal = {Expert opinion on biological therapy},
doi = {10.1080/14712598.2025.2576506},
url = {https://doi.org/10.1080/14712598.2025.2576506}
}RIS
TY - JOUR TI - Comparative efficacy and safety of biosimilar Bmab 1200 versus reference ustekinumab in moderate-to-severe plaque psoriasis: 52-week findings from the Phase 3 STELLAR-2 trial. AU - Szepietowski JC AU - Reich A AU - Feldman SR AU - Pulka G AU - Mekokishvili L AU - Tsiskarishvili N AU - Svarca I AU - Poder A AU - Singh G AU - Deodhar S AU - Kumar K AU - Marwah A AU - Loganathan S AU - Wolff-Holz E AU - Athalye SN PY - 2025 JO - Expert opinion on biological therapy DO - 10.1080/14712598.2025.2576506 UR - https://doi.org/10.1080/14712598.2025.2576506 ER -
APA
JC, S., A, R., SR, F., G, P., L, M., N, T., I, S., A, P., G, S., S, D., K, K., A, M., S, L., E, W., & SN, A. (2025). Comparative efficacy and safety of biosimilar Bmab 1200 versus reference ustekinumab in moderate-to-severe plaque psoriasis: 52-week findings from the Phase 3 STELLAR-2 trial.. Expert opinion on biological therapy. https://doi.org/10.1080/14712598.2025.2576506
Source records
- pubmed · retrieved 2026-09-25T21:09:16.535Z
- europe-pmc · retrieved 2026-09-25T21:09:16.540Z